Mankind Pharma to invest EUR 48 million for 70% of CAR-T developer ACTx
Mankind Pharma said on 15 October 2026 it will invest EUR 48 million for a 70% stake in Belgium's Armed Cell Therapeutics, its entry into CAR-T cell therapy for cancer.
Topic
CAR-T
The Handover
In a hospital, the handover is when one shift tells the next what changed and what to watch. Ours does the same for the business of healthcare, every weekday morning once it launches.
One email each weekday after launch. Unsubscribe at any time.